Why is accessibility such a crucial consideration of open access publishing, and how can we ensure content is sufficiently accessible?
What are the benefits of open access publishing, and how can we improve equity in academic and medical communications?
At a workshop on managing conflicts of interest in medicine, Chris Winchester, CEO of Oxford PharmaGenesis and co-founder of Open Pharma, argued for openness.
On 11–12 June 2019, over 60 pharma stakeholders met in Amsterdam at the
8th Annual Publication and Clinical Trial Transparency Conference to discuss the evolving landscape of clinical trial transparency.
On 15 May 2019, the Center for Biomedical Research Transparency (CBMRT) brought the stakeholders in academic publishing together to share their varying perspectives on research transparency and accessibility at the European Biomedical Transparency Summit (BMTS), in Paris.
Featuring pharma taking the lead on sharing clinical trial results, where preprints end up, and the identity of peer reviewers.
In order to protect the quality of clinical research it is vital for all trials to be represented in scientific literature for the benefit of scientific progress and research efficiency, and, ultimately, to better inform care for our patients in a timely manner.
Here’s our summary of key points from selected presentations at the 2018 European meeting of ISMPP.
Based on our experience, we believe that ORCID can make medical publishing faster and more transparent.
With CRediT, ORCID and Publons integrated into Editorial Manager®, we aim for these transparency tools to be easy, standard steps in the publishing process